


PHARMACOSTRUCTURAL INDEX

This index is a compilation of drugs published as monographs during the year in Drugs of the Future. Drugs are arranged in pharmacological groups together with their structural formulas or description to facilitate easy self-instruction of biological activities as they relate to molecular structural features.


ANTI-INFECTIVE THERAPY

Antibiotics and Antibacterial Drugs

1. NVC-422




2. Solithromycin




Antiviral Drugs

1. Cenicriviroc Mesilate





2. Daclatasvir Dihydrochloride




CARDIOVASCULAR DRUGS

Treatment of Heart Failure

1. LCZ-696




2. Lixivaptan



Treatment of Disorders of Gastric Emptying

1. Ulimorelin



DERMATOLOGIC DRUGS

Treatment of Psoriasis


1. Briakinumab

Immunoglobulin G₁, anti-(human interleukin-12 subunit β (IL-12 subunit p40, CLMF p40 or NKSF2)); human monoclonal γ 1 heavy chain (218-216')-disulfide with human monoclonal λ light chain, dimer (224-224':227-227')-bisdisulfide

HEMATOLOGIC DRUGS

Antiplatelet Drugs


1. Vorapaxar




ENDOCRINE DRUGS

Treatment of Diabetes

1. Canagliflozin



2. TAK-875



IMMUNOMODULATORS

Treatment of Autoimmune Disorders

1. Secukinumab

Human monoclonal IgG_{1k} antibody against IL-17A

NEUROLOGIC DRUGS

Treatment of Amyotrophic Lateral Sclerosis


1. SB-509

pVAX-1 DNA plasmid encoding the cytomegalovirus (CMV) promoter, three-finger ZFP (zinc finger protein) DNA-binding domain, the nuclear translocation signal from simian virus 40 large T antigen and the transactivation domain from the p65 subunit of the human nuclear factor NF- κ B, targeting the VEGF-A gene sequence: GGGGGTGA

GASTROINTESTINAL DRUGS

Treatment of Constipation


1. Velusetrag




ONCOLYTIC DRUGS

Oncolytic Drugs


1. Acadesine




2. Apricoxib



3. Crizotinib




4. ENMD-2076




5. Ganitumab

Immunoglobulin G₁, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimer


6. Gemcitabine Elaidate



7. Linsitinib



8. MDV-3100




9. NGR-hTNF

Human TNF fused with the NGR peptide that targets the tumor neovasculature by binding to CD13 (CNGRC peptide)


10. Obinutuzumab

Immunoglobulin G₁, anti-(human CD20 (antigen)) (human-mouse monoclonal GA101 heavy chain), disulfide with human-mouse monoclonal GA101 κ-chain, dimer


11. ON 01910.Na




12. Pomalidomide




13. Ponatinib




14. Regorafenib




15. TG-101348



16. TH-302



17. Tivantinib



18. Trastuzumab Emtansine


Immunoglobulin G₁, anti-(human p185neu receptor) (human–mouse monoclonal rhuMab HER2 γ 1-chain), disulfide with human–mouse monoclonal rhuMab HER2 light chain, dimer, tetraamide with N2'-[3-[[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]thio]-1-oxopropyl]-N2'-deacetylmaytansine

19. Veltuzumab

Immunoglobulin G₁, anti-(human CD20 (antigen)) (human–mouse monoclonal hA20 heavy chain), disulfide with human–mouse monoclonal hA20 κ -chain,

dimer


20. Vemurafenib



PSYCHOPHARMACOLOGIC DRUGS

Treatment of Depression


1. Lu-AA-21004



RENAL-UROLOGIC DRUGS

Treatment of Gout

1. Lesinurad Sodium



TREATMENT OF MUSCULOSKELETAL AND CONNECTIVE TISSUE DISEASES

Antiarthritic Drugs

1. Fostamatinib Disodium

